SCHEMBL20128964

SCHEMBL20128964

CCCCCCOCCCCCO[C@H]1C[C@@H](OCc2ccccc2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.43
TSHR P16473 2/20 0.43
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
CYP3A4 P08684 1/20 0.43
MAPK1 P28482 1/20 0.43
OPRM1 P35372 2/20 0.42
OPRL1 P41146 2/20 0.42
LMNA P02545 1/20 0.41
CETP P11597 3/20 0.40
HRH3 Q9Y5N1 2/20 0.40
TMEM97 Q5BJF2 1/20 0.40
CARM1 Q86X55 1/20 0.40
PRMT6 Q96LA8 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
PRMT8 Q9NR22 1/20 0.40
BCHE P06276 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSK P43235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20128961 0.96 TSHR (0.46) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL15887771 0.80 L3MBTL1 (0.57) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL15924398 0.80 L3MBTL1 (0.57) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL19227196 0.80 L3MBTL1 (0.57) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL20133212 0.79 MEN1 (0.48) L3MBTL1OPRM1OPRL1BCHECTSL
SCHEMBL25078767 0.78 L3MBTL1 (0.55) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL8263938 0.78 L3MBTL1 (0.55) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL28427678 0.78 L3MBTL1 (0.55) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL28286457 0.78 L3MBTL1 (0.55) ALDH1A1TSHRTDP1L3MBTL1CYP3A4
SCHEMBL8912892 0.78 L3MBTL1 (0.55) ALDH1A1TSHRTDP1L3MBTL1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN ALDH1A1 3804/4885TSHR 4013/4885TDP1 892/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 ALDH1A1 4249/4885TSHR 3954/4885TDP1 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.